Glioblastoma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

269 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Glioblastoma
NCT03722342: TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Active, not recruiting
1b
9
RoW
TTAC-0001 and pembrolizumab combination
PharmAbcine
Recurrent Glioblastoma
11/19
09/22
NCT04587830: ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Recruiting
1b
32
RoW
ADI-PEG20, Temozolomide
Polaris Group
Glioblastoma Multiforme (GBM)
02/27
05/27
ACTRN12612001050842: Valproic acid and Metformin to treat patients with brain tumours

Not yet recruiting
1
12
 
Flinders Centre for Innovation in Cancer, Flinders University/Flinders Medical centre, Flinders Centre for Innovation in Cancer, Flinders University/Flinders Medical centre
Brain tumours - Glioblastoma multiforme (GBM)
 
 
ACTRN12621001172897: A study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).

Recruiting
1
21
 
Accendatech AU Pty Ltd, Accendatech AU Pty Ltd
Glioblastoma Multiforme
 
 
ACTRN12623000956606: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies

Recruiting
1
33
 
Antido Therapeutics (Australia) Pty Ltd, Antido Therapeutics (Australia) Pty Ltd, George Clinical Pty Ltd
Locally Advanced Solid Tumours
 
 
NCT01165632: Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

Active, not recruiting
1
24
US
biopsy, biopsies, computed tomography, tomography, computed, therapeutic conventional surgery, radiation therapy treatment planning/simulation, radiation therapy, irradiation, radiotherapy, therapy, radiation, magnetic resonance imaging, MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, fluorine F 18 fluorodopa, (18)F-FDOPA, 18F-6- L-fluorodopa, 18F-DOPA, 18F-FDOPA
Mayo Clinic, National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma
11/13
12/24
NCT01394016: A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Checkmark For breast cancer
Jun 2014 - Jun 2014: For breast cancer
Checkmark For NSCLC
Jun 2014 - Jun 2014: For NSCLC
Checkmark ASCO 2014
More
Completed
1
225
US
Abemaciclib, LY2835219, Fulvestrant
Eli Lilly and Company
Advanced Cancer
05/14
04/22
NCT01586078: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors

Recruiting
1
100
US
pioglitazone hydrochloride, Actos, pioglitazone, laboratory biomarker analysis, external beam radiation therapy, EBRT, 3-dimensional conformal radiation therapy, 3D-CRT, conformal radiation therapy, intensity-modulated radiation therapy, IMRT, management of therapy complications, complications of therapy, management of
Comprehensive Cancer Center of Wake Forest University, National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma, Nonmalignant Neoplasm, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain
09/14
 
NCT01752491: A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Active, not recruiting
1
13
US
Ascorbate, Ascorbic Acid, Vitamin C, Temozolomide, Temodar, Radiation therapy, External beam radiation therapy
Joseph J. Cullen, MD, FACS, National Institutes of Health (NIH), National Cancer Institute (NCI)
Glioblastoma, GBM, Glioblastoma Multiforme
11/15
12/24
2007-001104-21: A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Ongoing
1
36
Europe
Delta-24-RGD Adenovirus,
VU Cancer Centre, Afdeling Geneeskundige Oncologie
Recurrent Glioblastoma Multiforme
 
 
ChiCTR-IPR-15006282: Bioequivalence of Temozolomide capsules to Chinese cancer patients in an open-label, randomised, single-dose, fasting, two-way crossover study

Not yet recruiting
1
24
 
T-R ;R-T
Beijing Shijitan Hospital Capital Medical University; BEIJING SL PHARM, BEIJING SL PHARM
Glioma
 
 
NCT02530502: Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Terminated
1
4
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temodal, Temodar
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Adult Glioblastoma
05/16
02/20
NCT01957956: Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Completed
1
21
US
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Mayo Clinic, National Cancer Institute (NCI)
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
11/16
11/16
ATTAC, NCT00639639: Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
1
42
US
tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
Gary Archer Ph.D., National Cancer Institute (NCI)
Malignant Neoplasms of Brain
04/17
06/22
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
LITESPARK 001, NCT02974738: A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Active, not recruiting
1
120
NA
Belzutifan, PT2977 Tablets, PT-2977, HIF-2α inhibitor, MK-6482, WELIREG™
Peloton Therapeutics, Inc.
Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Carcinoma, Clear Cell Adenocarcinoma, Glioblastoma, Glioblastoma, Adult, GBM, Glioblastoma Multiforme
01/18
04/25
NCT02444546: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Completed
1
6
US
Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Wild-type Reovirus, Reolysin
Mayo Clinic, National Cancer Institute (NCI)
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
07/18
11/22
NCT00268385: Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Active, not recruiting
1
83
US
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
10/18
04/25
ChiCTR-IIR-17013050: A Pharmacokinetics Study of Genolimzumab Injection

Not yet recruiting
1
72
 
Single administration of GB226 ;Multiple administration of GB226
Cancer Hospital Chinese Academy of Medical Sciences; Genor Biopharma Co. Ltd., company invest
China patients with advanced and/or relapsed solid tumor/lymphoma
 
 
ChiCTR-OIC-17013604: A phase I study for evaluation of the safety, tolerability and pharmacokinetics of dose-escalation ACT001 in patients with advanced glioblastoma

Recruiting
1
15
 
ACT001
Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute&Hospital, funds raise by sponsor
advanced Glioma
 
 
NCT03347097: Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme

Active, not recruiting
1
40
RoW
TIL, PD1-TIL
Huashan Hospital, Shanghai Cell Therapy Research Institute
Glioblastoma Multiforme
01/20
12/21
NCT02133183: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Terminated
1
40
US
Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
01/20
10/23
NCT02457845: HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Completed
1
13
US
G207
Gregory K. Friedman, MD, Food and Drug Administration (FDA), National Center for Advancing Translational Sciences of the National Institutes of Health, Cannonball Kids' Cancer Foundation, Rally Foundation for Childhood Cancer Research, Hyundai Hope On Wheels, St. Baldrick's Foundation, United States Department of Defense, Andrew McDonough B+ Foundation, Kaul Pediatric Research Institute, NIH/National Cancer Institute Cancer Center Support Grants to the University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center, Kelsie's Crew, Eli's Block Party Childhood Cancer Foundation, Eli Jackson Foundation, Jaxon's F.R.O.G. Foundation, Battle for a Cure Foundation, Sandcastle Kids
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
06/20
01/24
NCT03223103: Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Active, not recruiting
1
13
US
Poly-ICLC, Hiltonol®, Tumor Treating Fields, Optune®, Peptides, Personalized peptides
Albert Einstein College of Medicine, NovoCure Ltd.
Glioblastoma
07/20
05/25
NCT03170141: Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Enrolling by invitation
1
20
RoW
Antigen-specific IgT cells
Shenzhen Geno-Immune Medical Institute
Glioblastoma Multiforme of Brain, Glioblastoma Multiforme
08/20
12/23
ChiCTR1800015808: Pilot Clinical Study of Chemo-Cocktail (TTF) for Recurrent Glioblastoma

Recruiting
1
10
 
temmozoldmide+tranilast+fasudil
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, No
Recurrent Glioblastoma
 
 
NCT02869243: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

Completed
1
15
Europe, RoW
hrBMP4, Recombinant Bone Morphogenic Protein-4, Device:Intracranial Catheter
Stemgen, ORION Clinical Services
Glioblastoma
10/20
06/21
NCT01269424: BG & TMZ Therapy of Glioblastoma Multiforme

Completed
1
10
US
MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Stanton Gerson MD, National Cancer Institute (NCI)
Glioblastoma Multiforme
12/20
09/22
NCT01922076: Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Completed
1
46
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
12/20
09/22
NCT02142803: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
1
50
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Onbevzi, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228
National Cancer Institute (NCI)
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Cancer, Solid Neoplasm, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
12/20
10/24
NCT03914768: Immune Modulatory DC Vaccine Against Brain Tumor

Enrolling by invitation
1
10
RoW
Immunomodulatory DC vaccine to target DIPG and GBM
Shenzhen Geno-Immune Medical Institute, Shenzhen Hospital of Southern Medical University, Shenzhen Children's Hospital
Diffuse Intrinsic Pontine Glioma or Glioblastoma
01/21
12/22
HUTMZ, NCT03463733: Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

Recruiting
1
54
Europe
Hydroxyurea, Hydroxycarbamide, Temozolomide, Temodar
M.E. van Linde, Massachusetts General Hospital
Glioma, Glioblastoma
06/21
06/22
NCT03360708: Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

Completed
1
20
US
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Mayo Clinic, National Cancer Institute (NCI)
Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
06/21
06/21
SPARE, NCT03477110: Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Completed
1
30
US
Temozolomide, 362856, Temcad, Temodal, Methazolastone, Temodar, Radiation Therapy, Cancer Radiotherapy, Irradiate, RT, NovoTTF-200A Device, Optune, Tumor Treating Fields Therapy, Alternating Electric Field Therapy
Sidney Kimmel Cancer Center at Thomas Jefferson University, NovoCure Ltd.
Glioblastoma
04/21
01/24
NCT01849146: Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Active, not recruiting
1
74
US
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
07/21
03/25
NCT02386826: INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Completed
1
65
US
INC280, INCB28060, bevacizumab, Avastin
SCRI Development Innovations, LLC, Novartis
Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
07/21
08/23
NCT03451799: Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma

Active, not recruiting
1
21
US
Ketogenic Diet, Standard-of-care radiation, Standard-of-care Temozolomide
Jethro Hu
GBM, Glioblastoma
09/21
05/26
NCT03426891: Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Completed
1
21
US
Pembrolizumab, Keytruda, immunotherapy, Vorinostat, Zolinza™, chemotherapy, histone deacetylase inhibitor, Temozolomide, Temodar, TMZ, Radiotherapy, radiation therapy
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Glioblastoma, Brain Tumor, GBM
10/21
06/23
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Active, not recruiting
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT05108012: Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients

Recruiting
1
5
RoW
NK cell therapy
Royan Institute, Tehran University of Medical Sciences
Glioblastoma Multiform, Recurrent Glioblastoma
11/21
04/22
NCT03344250: Phase I EGFR BATs in Newly Diagnosed Glioblastoma

Active, not recruiting
1
18
US
EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
University of Virginia
Glioblastoma, Glioblastoma Multiforme
12/21
12/24
NCT04716699: Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

Completed
1
12
US
Biospecimen Collection, Lidocaine, .omega.-Diethylamino-2,6-dimethylacetanilide, 2-(Diethylamino)-2'',6''-acetoxylidide, Cuivasil, Duncaine, Leostesin, Lidothesin, Lignocaine, Rucaina, Resection, Surgical Resection
Kiarash Shahlaie, M.D., Ph.D., National Cancer Institute (NCI)
Glioblastoma
12/21
01/22
NCT03043391: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Completed
1
8
US
Polio/Rhinovirus Recombinant (PVSRIPO)
Istari Oncology, Inc., Solving Kids' Cancer, The Andrew McDonough B+ Foundation, Duke University
Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
03/22
03/22
NCT02658981: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Completed
1
63
US
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, BMS-936558, Nivolumab, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137, urelumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
04/22
10/23
NCT03971734: Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Terminated
1
7
US
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
04/22
10/23
NCT04015700: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Active, not recruiting
1
9
US
Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, GNOS-PV01, Vaccine, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12, INO-9012
Washington University School of Medicine, Geneos Therapeutics, The Foundation for Barnes-Jewish Hospital
Glioblastoma
05/22
12/24
M032-HSV-1, NCT02062827: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

Active, not recruiting
1
29
US
M032 (NSC 733972)
University of Alabama at Birmingham, National Cancer Institute (NCI)
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
09/22
09/24
NCT03995706: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Completed
1
26
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio, Gilead Sciences
Glioblastoma
06/22
03/24
ACTRN12616000228482: A study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors

Completed
1
25
 
Accendatech AU Pty Ltd, Accendatech AU Pty Ltd
Solid tumors
 
 
8479217, NCT06469138: A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

Completed
1
6
Europe
Bemcentinib, BGB324
BerGenBio ASA
Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19
09/22
09/22
ChiCTR2000034068: Nimotuzumab Combined with Intensity Modulated Radiotherapy and Temozolamide Chemotherapy for Primary Glioblastoma

Not yet recruiting
1
30
 
Nimotuzumab Combined with Intensity Modulated Radiotherapy and Temozolamide Chemotherapy
The Third Hospital of Peking University; The Third Hospital of Peking University, Self-financing
Glioblastoma
 
 
NCT03956706: Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas

Withdrawn
1
36
US
Stereotactic Radiosurgery, Gamma Knife
Northwell Health
Glioblastoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Malignant Glioma
09/22
09/22
NCT02323880: Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Checkmark From trial for r/r pediatric solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From trial for r/r pediatric solid tumors at ESMO 2020
Active, not recruiting
1
59
US
Pharmacological Study, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Children's Oncology Group, National Cancer Institute (NCI)
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
09/22
09/24
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
SAS-GKRS, NCT04205357: Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

Completed
1
24
Europe
Sulfasalazine, Stereotactic radiosurgery
Haukeland University Hospital, Norwegian Cancer Society, Northwell Health, Weill Medical College of Cornell University, University of Bergen, Helse Stavanger HF
Glioma, Glioblastoma, Recurrent Glioblastoma
10/22
10/22
PNOC016, NCT03893487: Fimepinostat in Treating Brain Tumors in Children and Young Adults

Active, not recruiting
1
30
Europe, US
Fimepinostat, CUDC-907, Therapeutic Conventional Surgery
Sabine Mueller, MD, PhD, Pediatric Neuro-Oncology Consortium, Cannonball Kids' Cancer Foundation, Curis, Inc.
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
10/22
08/27
NCT04826393: ASP8374 + Cemiplimab in Recurrent Glioma

Active, not recruiting
1
14
US
ASP8374, cemiplimab, Libtayo
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals, Astellas Pharma Inc
Glioblastoma, Recurrent Glioblastoma
10/22
12/24
NCT04809805: A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

Terminated
1
5
US
BAY2666605
Bayer
Metastatic Melanoma and Other Solid Tumors
11/22
04/23
NCT03961971: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Active, not recruiting
1
16
US
MBG453, spartalizumab, stereotactic radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Novartis Pharmaceuticals
Glioblastoma Multiforme
11/22
09/25
NCT00102648: Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Active, not recruiting
1
35
US
Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
12/22
12/22
NCT05131763: NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Recruiting
1
3
RoW
NKG2D-based CAR T-cells
Fudan University, KAEDI
Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
12/22
12/23
NCT02709226: Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Completed
1
17
US
Radiation
National Cancer Institute (NCI)
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
12/22
07/23
NCT05201326: Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

Recruiting
1
20
RoW
Bevacizumab，Irinotecan and Re-radiotherapy
Ruijin Hospital
Recurrent Glioblastoma
12/22
12/24
NCT03539731: [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Terminated
1
27
US
Fluorine F 18 DASA-23, [18F]DASA-23; [18F]DASA23; 18F-DASA-23; 1-((2-Fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine; F18-labeled Pyruvate Kinase M2 Inhibitor DASA-23; F18-labeled PKM2 Inhibitor, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Guido A. Davidzon, MD, SM
Healthy Subject, Intracranial Neoplasm, Glioblastoma
12/22
12/22
NCT03536728: Oral AMXT 1501 Dicaprate in Combination With DFMO

Completed
1
56
US
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
12/22
04/23
NCT04552886: Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma

Completed
1
17
US
TH-1 Dendritic Cell Immunotherapy
The Cooper Health System, Baylor College of Medicine, Philadelphia College of Osteopathic Medicine
Glioblastoma
12/23
12/23
NCT04396717: Safety Study of Pritumumab in Brain Cancer

Recruiting
1
42
US
Pritumumab
Nascent Biotech, Hoag Memorial Hospital Presbyterian
Malignant Primary Brain Tumors, Brain Metastases, Adult
01/23
06/23
NCT04608812: Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

Terminated
1
7
US
OS2966, Gadoteridol
OncoSynergy, Inc., Infuseon Therapeutics, Inc.
Glioma, Malignant, High Grade Glioma, Glioblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma
02/23
02/23
NCT02933736: Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

Active, not recruiting
1
48
US
Ribociclib, LEE011
Nader Sanai, Novartis, Ivy Brain Tumor Center, Barrow Neurological Institute
Glioblastoma Multiforme, Meningioma
03/23
01/25
NCT03714334: DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

Terminated
1
16
Europe
DNX-2440 injection
Clinica Universidad de Navarra, Universidad de Navarra, DNAtrix, Inc.
Glioblastoma, Glioblastoma, Adult
04/23
04/23
CDX527-01, NCT04440943: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Completed
1
27
US
CDX-527
Celldex Therapeutics
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
04/23
04/23
NCT03493932: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Completed
1
21
US
Nivolumab, BMS-986016
National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma
04/23
06/23
NCT04424966: Infigratinib in Recurrent High-Grade Glioma Patients

Terminated
1
7
US
Infigratinib
Nader Sanai, Ivy Brain Tumor Center, Barrow Neurological Institute, QED Therapeutics
Glioma, Glioblastoma, GBM
04/23
04/23
NCT05095441: A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Not yet recruiting
1
51
US
C5252
ImmVira Pharma Co. Ltd
Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
04/23
04/26
GLIO-XS15, NCT04842513: Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma

Recruiting
1
15
Europe
Multipeptide plus XS15
University Hospital Tuebingen
Glioblastoma Multiforme of Brain
08/24
08/25
NCT02654964: Cancer Stem Cell High-Throughput Drug Screening Study

Completed
1
9
US
Combination Drug Therapy
Swedish Medical Center
Glioblastoma Multiforme
11/21
06/23
NCT05341947: Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

Not yet recruiting
1
10
US
Activated T cells
Jeremy Rudnick, M.D, Kairos Pharma
Recurrent Glioblastoma
12/25
12/26
NCT04757662: Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Completed
1
18
US
Tadalafil, Cialis, Adcirca
Washington University School of Medicine
Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
06/23
06/23
ChiCTR2000032402: Clinical trial and therapeutic mechanism of novel oncolytic virus tumor therapy: a clinical study of Ad-TD-nsIL12 in the treatment of recurrent glioblastoma

Not yet recruiting
1
30
 
Novel oncolytic virus Ad-TD-nsIL12
Sanbo Brain Hospital Capital Medical University; Sanbo Brain Hospital Capital Medical University, Central Government Funds
Glioblastoma
 
 
PhAST, NCT05495295: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

Recruiting
1
149
Europe
PhOx430, Dose Escalation Phase - STEP 1 and STEP 2, Dose Escalation Phase - STEP 3 (Dosing-optimization Cohort)
Phost'In Therapeutics
Malignant Tumor, Advanced Solid Tumor, Glioblastoma Multiforme, Metastatic Cancer
07/24
07/27
NCT05868083: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recruiting
1
16
RoW
SNC-109 CAR-T Cells
Shanghai Simnova Biotechnology Co.,Ltd., Chinese PLA General Hospital
Recurrent Glioblastoma Multiforme
05/24
08/24
NCT05054400: Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR

Withdrawn
1
20
US
F18 Fluciclovine, Standard of Care
M.D. Anderson Cancer Center
Brain Metastases, Cancer, Gliomas, Glioblastoma
08/23
08/23
NCT04047303: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Terminated
1
20
Europe, US
CC-90010
Celgene
Astrocytoma, Glioblastoma
06/24
06/24
RIT in GBM, NCT05533242: Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment

Recruiting
1
15
Europe
Lu-177 labeled 6A10-Fab-fragments
University Hospital Muenster, Isotope Technologies Munich (ITM) Oncologics, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Glioblastom WHO Grade 4
06/25
06/25
NCT04324840: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Terminated
1
184
Europe, US
CC-90010, Temozolomide, Radiotherapy
Celgene
Glioblastoma
07/24
07/24
NCT06193538: The Safety and Effectiveness of NV-A01 in Glioma Patients

Recruiting
1
15
RoW
Recombinant NV-A01 adenovirus injection
First Affiliated Hospital of Wannan Medical College
Advanced Glioblastoma Patients
12/24
07/25
NCT04135807: Implantable Microdevice In Primary Brain Tumors

Recruiting
1
12
US
Microdevice, Implantable Microdevice
Oliver Jonas, PhD
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
09/23
02/24
NCT01430351: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Active, not recruiting
1
144
US
Mefloquine, Memantine Hydrochloride, Ebixia, Namenda, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
09/25
09/25
NCT03389802: Phase I Study of APX005M in Pediatric CNS Tumors

Active, not recruiting
1
32
US
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
Pediatric Brain Tumor Consortium, American Lebanese Syrian Associated Charities (ALSAC), Pyxis Oncology, Inc, Solving Kids' Cancer, Ty Louis Campbell Foundation, A Kids' Brain Tumor Cure Foundation, National Cancer Institute (NCI)
Glioblastoma Multiforme, High-grade Astrocytoma NOS, CNS Primary Tumor, Nos, Ependymoma, NOS, Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
09/23
09/24
NCT03896568: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recruiting
1
36
US
Oncolytic Adenovirus Ad5-DNX-2401, Ad5-Delta24RGD, DNX-2401, DNX2401, Oncolytic Ad5-Delta 24RGD, Oncolytic Adenovirus Ad5-Delta 24RGD, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, DNAtrix, Inc.
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
09/27
09/27
CARTREMENDOUS, NCT05063682: The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients

Active, not recruiting
1
10
Europe, RoW
EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
Chembrain LTD, University of Oulu, Jyväskylä Central Hospital, Apollo Hospital, New Delhi, India
Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant
10/23
10/23
NCT05076513: Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

Recruiting
1
42
US
Niraparib, Zejula, Radiation therapy
Nader Sanai, Barrow Neurological Institute, Ivy Brain Tumor Center, University of California, San Francisco, GlaxoSmithKline
Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
08/24
02/25
NCT04834778: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Completed
1
23
US
HC-5404-FU, HC-5404
HiberCell, Inc., Covance
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
12/23
01/24
NCT03965494: AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Terminated
1
10
US
BGB 324 (before surgery), AXL Inhibitor BGB324, Bemcentinib, BGB 324 (after surgery)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), BerGenBio ASA
Brain and Central Nervous System Tumors
10/23
10/23
NCT01421524: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Completed
1
271
Europe, US
CC-122
Celgene
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
11/23
11/23
CAR2BRAIN, NCT03383978: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting
1
42
Europe
NK-92/5.28.z, Ezabenlimab
Johann Wolfgang Goethe University Hospital, DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, LOEWE Center Frankfurt Cancer Institute, German Cancer Research Center
Glioblastoma
12/25
06/26
NCT02669173: Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Active, not recruiting
1
12
US
Capecitabine, Bevacizumab
Case Comprehensive Cancer Center
Glioblastoma
03/19
11/24
NCT03705351: Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Terminated
1
7
US
Tumor Treating Fields, Optune, Novocure, Temozolomide, Temodar, Radiation Therapy
Providence Health & Services, University of California, San Francisco, NovoCure Ltd.
Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
02/21
02/22
NCT04642937: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Active, not recruiting
1
24
US
Treatment with hP1A8
OX2 Therapeutics
Glioblastoma
11/23
11/24
NCT04474353: Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1
12
US
Optune, Gadolinium, Contrast agent, Temozolomide, Stereotactic radiosurgery (SRS)
Stanford University, NovoCure Ltd.
Glioblastoma, Newly Diagnosed Glioblastoma
10/24
11/24
 

Download Options